ADRIATIC: Durvalumab (D) as consolidation treatment (tx) for patients (pts) with limited-stage small-cell lung cancer (LS-SCLC).

医学 杜瓦卢马布 肿瘤科 内科学 阶段(地层学) 肺癌 癌症 免疫疗法 彭布罗利珠单抗 古生物学 生物
作者
David R. Spigel,Ying Cheng,Byoung Chul Cho,К. К. Лактионов,Jian Fang,Yuanbin Chen,Yoshitaka Zenke,Ki Hyeong Lee,Qiming Wang,Alejandro Navarro,Reyes Bernabé,E.L. Buchmeier,John W. C. Chang,Isamu Okamoto,Sema Sezgin Göksu,A. Badzio,Bethany Gill,Hema Gowda,Haiyi Jiang,Suresh Senan
出处
期刊:Journal of Clinical Oncology [Lippincott Williams & Wilkins]
卷期号:42 (17_suppl): LBA5-LBA5 被引量:45
标识
DOI:10.1200/jco.2024.42.17_suppl.lba5
摘要

LBA5 Background: The standard of care (SoC) for pts with LS-SCLC is concurrent platinum-based chemoradiotherapy (cCRT) ± prophylactic cranial irradiation (PCI). ADRIATIC (NCT03703297), a phase 3, randomized, double-blind, placebo (PBO)-controlled, multicenter, global study, assessed D ± tremelimumab (T) as consolidation tx for pts with LS-SCLC who had not progressed after cCRT. Here we report results for D vs PBO from the first planned interim analysis (IA). Methods: Eligible pts had stage I–III LS-SCLC (stage I/II inoperable) and WHO performance status 0/1, and had not progressed after cCRT. PCI was permitted before randomization. Pts were randomized 1–42 days after cCRT to D 1500 mg + PBO, D 1500 mg + T 75 mg, or PBO + PBO every 4 weeks (Q4W) for 4 cycles, followed by D (D±T arms) or PBO Q4W until investigator-determined progression or intolerable toxicity, or for a maximum of 24 months (mo). The first 600 pts were randomized in a 1:1:1 ratio; subsequent pts were randomly assigned 1:1 to D or PBO. Randomization was stratified by stage (I/II vs III) and receipt of PCI (yes vs no). The dual primary endpoints were OS and PFS (blinded independent central review per RECIST v1.1) for D vs PBO. OS and PFS for D+T vs PBO were alpha-controlled secondary endpoints. Results: 730 pts were randomized, including 264 to D and 266 to PBO. Baseline characteristics and prior tx were well balanced between arms. Radiation schedule in the D vs PBO arms was once daily in 73.9% vs 70.3% of pts and twice daily in 26.1% vs 29.7%; 53.8% of pts in each arm received PCI. At this IA (data cutoff 15Jan2024), median (range) duration of follow-up for OS and PFS in censored pts was 37.2 (0.1–60.9) and 27.6 (0.0–55.8) mo, respectively. OS was significantly improved with D vs PBO (HR 0.73 [95% CI 0.57–0.93]; p=0.0104; median OS 55.9 [95% CI 37.3 – not estimable] vs 33.4 [25.5–39.9] mo; 24-mo OS rate 68.0% vs 58.5%; 36-mo OS rate 56.5% vs 47.6%). PFS was also significantly improved with D vs PBO (HR 0.76 [95% CI 0.61–0.95]; p=0.0161; median PFS 16.6 [95% CI 10.2–28.2] vs 9.2 [7.4–12.9] mo; 18-mo PFS rate 48.8% vs 36.1%; 24-mo PFS rate 46.2% vs 34.2%). Tx benefit was generally consistent across predefined pt subgroups for both OS and PFS. With D vs PBO, maximum grade 3/4 all-cause adverse events (AEs) occurred in 24.3% vs 24.2% of pts; AEs led to tx discontinuation in 16.3% vs 10.6% of pts and to death in 2.7% vs 1.9%. Any-grade pneumonitis/radiation pneumonitis was reported in 38.0% vs 30.2% of pts with D vs PBO (maximum grade 3/4 in 3.0% vs 2.6%). The D+T arm remains blinded until the next planned analysis. Conclusions: D as consolidation tx after cCRT demonstrated a statistically significant and clinically meaningful improvement in OS and PFS compared with PBO in pts with LS-SCLC. D was well tolerated and AEs were consistent with the known safety profile, with no new signals observed. These data support consolidation D as a new SoC for pts with LS-SCLC who have not progressed after cCRT. Clinical trial information: NCT03703297 .
最长约 10秒,即可获得该文献文件

科研通智能强力驱动
Strongly Powered by AbleSci AI
科研通是完全免费的文献互助平台,具备全网最快的应助速度,最高的求助完成率。 对每一个文献求助,科研通都将尽心尽力,给求助人一个满意的交代。
实时播报
orixero的应助被Rainvin采纳,获得10
1秒前
自信的牛排完成签到 ,获得积分10
1秒前
fdyy1完成签到,获得积分10
2秒前
漫漫发布了新的文献求助10
2秒前
姜OMG发布了新的文献求助10
2秒前
cgliuhx发布了新的文献求助10
2秒前
QQ发布了新的文献求助10
2秒前
小小发布了新的文献求助10
3秒前
Dee完成签到,获得积分10
3秒前
所所的应助被Re采纳,获得10
3秒前
啊啊啊完成签到,获得积分10
3秒前
麦当劳没有Creazy4完成签到,获得积分10
4秒前
5秒前
5秒前
6秒前
6秒前
大个的应助被angki77采纳,获得10
6秒前
6秒前
专注的代天完成签到,获得积分10
7秒前
Gatto完成签到,获得积分10
7秒前
8秒前
8秒前
lyx5266发布了新的文献求助10
8秒前
9秒前
ccdw发布了新的文献求助10
9秒前
10秒前
10秒前
阿泽发布了新的文献求助10
10秒前
大尾猫完成签到 ,获得积分10
11秒前
在水一方的应助被风中的宛白采纳,获得10
11秒前
carol0705发布了新的文献求助10
12秒前
愉快小凝发布了新的文献求助10
12秒前
13秒前
FashionBoy的应助被QQ采纳,获得10
13秒前
可爱的函函的应助被mm采纳,获得10
13秒前
木青完成签到,获得积分10
14秒前
Voiceless的应助被专注的半雪采纳,获得50
14秒前
15秒前
武子阳完成签到 ,获得积分10
15秒前
阿泽完成签到,获得积分10
16秒前
高分求助中
(应助此贴封号)【重要!!请各用户(尤其是新用户)详细阅读】【科研通的精品贴汇总】 10000
拉伸高分子熔体中缠结行为的模拟和小角中子散射研究 1700
The World Atlas of Wine 9th edition 1000
奈特基础组织学:配套组织病理学(第4版)(Netter's Essential Histology With Correlated Histopathology) 800
八旗制度の研究 600
Boundaries and Bodhisattvas 500
高分子基功能界面水蒸发材料与应用研究 500
热门求助领域 (近24小时)
化学 材料科学 医学 生物 纳米技术 计算机科学 工程类 有机化学 化学工程 生物化学 物理 复合材料 内科学 催化作用 光电子学 人工智能 细胞生物学 无机化学 物理化学 数学
热门帖子
关注 科研通微信公众号,转发送积分 8181408
求助须知:如何正确求助?哪些是违规求助? 9571330
关于积分的说明 21817615
捐赠科研通 7777856
什么是DOI,文献DOI怎么找? 3433479
关于科研通互助平台的介绍 2557696
邀请新用户注册赠送积分活动 2479527